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Background: SUBLIVAC FIX Birch (SUB-B) is a liquid oral preparation of Betula verrucosa pollen extract for the
treatment of allergic rhinitis/rhinoconjuctivitis induced by birch pollen. The major allergen content of SUB-B and
Staloral Birch (Stal-B) have been shown to be comparable. In order to compare the clinical efficacy and safety of
both products, the present study was designed to investigate efficacy of treatment with SUB-B compared to Stal-B
by means of reduction in allergy symptoms assessed by a titrated nasal provocation test (TNPT) in subjects suffering
from IgE mediated allergy complaints triggered by birch pollen.
Methods: A prospective, randomized, open, blinded endpoint (PROBE), controlled, single-centre study in 74 birch
allergic adults was performed. Treatment consisted of either SUB-B (10,000 AUN/ml) or Stal-B (initial phase 10 I.R./ml
and maintenance phase 300 I.R./ml) for 16–20 weeks at maintenance dose. The primary efficacy outcome was
defined by the difference in change of the TNPT-threshold dose between the two treatment groups at baseline
and after completion of treatment. Secondary outcomes included determination of birch pollen specific IgE and
IgG levels, safety lab and ECG. During the first 30 days of treatment, subjects were requested to fill out a diary
concerning compliance with study medication, occurrence of AEs and the use of concomitant medication.
Results: Analysis of the primary efficacy parameter showed that the percentage of subjects showing a beneficial
treatment effect was similar in both treatment groups, 33.3% for SUB-B vs. 31.4% for Stal-B in the intention to treat
population. Evaluation of the immunologic response, showed that treatment with SUB-B and Stal-B induced similar
increases (approximately 2 times) in IgE, IgG and IgG4 specific for Bet v 1.
In total, 143 related adverse events (AEs) were reported. The majority of the AEs was of mild intensity. The same
pattern of AEs was observed for both products. No clinically relevant changes in other safety parameters, such as
safety laboratory parameters, vital signs, physical examination and ECGs were observed.
Conclusion: Taken together, treatment with both products was effective by means of reduction in allergic
symptoms during a TNPT. In addition, safety analysis revealed a good tolerability of both SLIT extracts.
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Allergic rhinitis is a global health problem, affecting all
ethnic groups and ages and is estimated to affect 10-25%
of the population [1,2]. Allergic rhinitis/rhinoconjuncti-
vitis may significantly impair social life, school perform-
ance, work productivity and sleep in both adults and
paediatric populations [1]. Moreover, if left untreated,
allergic rhinitis/rhinoconjunctivitis is considered to be
one of the major risk factors for the development of
asthma [3-5].
Allergen specific immunotherapy is considered as an
effective treatment for respiratory allergies. Specific im-
munotherapy is the only (causal) treatment modality
with the capability of changing the natural course of the
disease and thereby preventing its exacerbation and pos-
sible progression from rhinitis/rhinoconjunctivitis to
asthma [4-6].
Sublingual immunotherapy (SLIT) is considered a vi-
able and safe alternative to subcutaneous immunother-
apy and is widely used in European countries [6,7]. The
efficacy of SLIT in allergic rhinitis/rhinoconjunctivitis
induced by various allergens, has been confirmed in
multiple studies and, recently, sustained clinical effects,
i.e. maintenance of significant and clinically relevant
efficacy during two to three treatment years [8], of this
form of SIT has been demonstrated [9-11].
The amount of allergen administered is crucial for both
efficacy and safety of specific immunotherapy [11,12]. The
major allergen in birch pollen is Betula verrucosa 1 (Bet v 1)
and a recent study investigated the content of Bet v 1 in
different SLIT products with a validated ELISA immuno-
assay [13]. The results showed that the amount of Bet v 1
(daily maintenance dose) in SUB-B and Stal-B was 46.7 μg
and 25.4 μg respectively, both representing a high dose of
major allergen [13]. Subsequently, the current study was
performed to investigate the clinical efficacy and safety of
SUB-B. Stal-B was chosen as a comparator product since
this product is registered in Germany and has demon-
strated efficacy in a previous clinical trial [14]. The
primary objective of the study was to show, on an explora-
tory basis, that treatment with SUB-B is non-inferior to
Stal-B by means of reduction in allergy symptoms
assessed by TNPT in subjects suffering from IgE mediated
allergy complaints triggered by birch pollen. Additionally
the effect of treatment on allergen specific immunoglobu-
lins was assessed. Furthermore, data with regards to safety
of the product were obtained.
Materials and methods
Subjects
Seventy-four subjects with allergic rhinoconjunctivitis due
to birch pollen with or without mild intermittent asthma
(controlled by ß2 agonist use only) were included. A posi-
tive SPT (diameter ≥3 mm) for birch pollen (HAL AllergyB.V., Leiden, The Netherlands), a positive specific serum
anti birch IgE test (>1 U/ml) and a positive TNPT with
a birch pollen extract (HAL Allergy B.V., Leiden, The
Netherlands) containing a concentration of 10, 100 or
1,000 AU/ml before start of treatment were required and
were determined at the study site (Center for Rhinology
and Allergology Wiesbaden). The main exclusion criteria
were clinically relevant symptoms due to perennial aller-
gies, chronic asthma or emphysema, with an FEV1 < 70% of
predicted value, allergen specific immunotherapy within
the past 5 years, completed or ongoing anti-IgE therapy,
pregnancy, chronic or malignant diseases, drug or alcohol
abuse and psychiatric disorders.
Written informed consent was obtained from all
subjects. The study protocol was approved by the
Ethik-Kommission der Landesärztekammer Hessen,
Frankfurt-am-Main, Germany (approval no. FF 24/
2009). The study was conducted in compliance with
the latest version of the Declaration of Helsinki (DoH/
Oct2008).
Study design
The study was designed as a prospective, randomized,
open, blinded endpoint, controlled, single centre study
in Germany. The first patient was screened on 13 July
2009 and the last patient completed the study on 02
March 2010. Patients initiated treatment from 07 August
2010 until 23 October 2010, treatment duration was
16 weeks on average. All patients finished the study be-
fore the start of the birch pollen season, so it can be
seen as a “pre-seasonal” schedule. Outcome measures
were determined outside the birch pollen season, which
started at the end of March 2010 in Germany. Due to
the unavailability of Stal-B placebo, a blinded treatment
using a three-arm, double-blind, double-dummy placebo-
controlled design was not feasible. However, the assessment
of the primary parameter was blinded, i.e. the assessor of
the TNPT was not informed on the treatment group of
subjects, enabling an independent assessment of the test.
The assessor confirmed blinding by signing a statement of
independent assessment.
Subjects were randomized to receive either SUB-B or
Stal-B at a 1:1 ratio. SLIT consisted of either SUBLIVAC
FIX Birch (10,000 AUN/ml; HAL Allergy BV, Leiden,
The Netherlands) or Staloral Birch (10 I.R./ml and 300 I.
R./ml; Stallergenes S.A., Antony, France), taken once
daily and was started at the baseline visit. Treatment
started with an up-dosing phase lasting 5 days for SUB-
B and 9 days for the Stal-B preparations (6 days with vial
10 I.R./ml and 3 days with vial 300 I.R./ml). Thereafter
the maintenance phase started and treatment was con-
tinued at a constant dose, from day 6 at 5 drops for
SUB-B, and from day 10 at 4 puffs for Stal-B (vial 300 I.
R./ml) for 16–20 weeks. The amount of Bet v 1 in the
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fied with a validated ELISA immunoassay using Bet v 1
monoclonal antibodies (INDOOR Biotechnologies Ltd.,
Cardiff, UK).
During the first month of treatment, subjects were re-
quested to fill out a diary concerning compliance with
study medication, occurrence of AEs and the use of con-
comitant medication. Subjects visited the study centre
before (screening and baseline visit), 1 month and 16–20
weeks after start of treatment (end of study). Vials of
SLIT were returned to check compliance after four
weeks and at the end of the trial.Assessment of efficacy
The titrated nasal provocation test (TNPT) was chosen
as primary efficacy parameter. The TNPT-threshold dose
was assessed at start of the study and after completion
of treatment for each subject for both treatment groups,
based on the German position paper on nasal allergen-
challenge [15]. The procedure is briefly described as
follows: before the provocation test subjects were accli-
matized for 30 minutes in the test room. Rhinoscopy
was performed prior to the measurement. Both the sum
of reaction scores and nasal flow were assessed. Reaction
scores of secretion (score 0–2), irritation/sneezing (score
0–2) and systemic symptoms (score 0–2) were deter-
mined (maximum score: 6). As an objective parameter,
nasal airflow was additionally measured using rhinoma-
nometry (MasterScopeRhino, CardinalHealth, Hoechberg,
Germany). Flow rates at 150 Pa were obtained for both
nostrils (ml/s). Sequential (allergen) dilutions were sprayed
into the nose, after approximately 10 minutes the flow in
both nostrils and symptom scores were determined. If the
flow was more than 40% lower than the flow of the same
side obtained with the previous measurement or the sum
of the reaction scores was more than 3, the TNPT was
regarded positive.
The allergen-challenge was performed with a solution
containing diluent, 10 AU/ml, 100 AU/ml and 1,000 AU/
ml (10,000 AU/ml, HAL-Allergy, Leiden, The Netherlands)
at start of the study until a positive result was obtained. At
the end of the study the TNPT was repeated with diluent,
10, 100, 1,000 or 10,000 AU/ml until a positive result
was obtained. Dilutions were made on the day of the
test from the stock solution of 10,000 AU/ml and one
batch was used for all provocation tests. For each sub-
ject a comparison of the first and second TNPT was
made. The treatment effect was scored as beneficial if
the threshold dose of the second TNPT was higher
than that of the first TNPT (Table 1). If this was not
the case, the treatment effect was scored as non-
beneficial. If a second TNPT was not performed, the
result of the first TNPT was used for replacement ofthe missing second test results (Last Observation Carried
Forward (LOCF-)principle).
Immunological measurements
Blood samples for determination of specific IgE, IgG and
IgG4 were taken at baseline (before start of treatment) and
at the end of the study. Birch and Bet v 1 specific IgE and
IgG4 and Bet v 1 specific IgG antibodies were determined
by ImmunoCAP® (Thermo Scientific, Uppsala, Sweden).
Sera were analysed according to the specifications of the
manufacturer at the Department of Experimental Immun-
ology, AMC, University of Amsterdam, The Netherlands.
Safety measurements
For safety measurements, adverse events (AE) were moni-
tored throughout the study. A 30 minute observation
period after the first administration of study medication
was incorporated to observe immediate AE’s [6]. During
the first month of treatment, subjects kept a daily record of
all reactions occurring after taking the study medication.
Before start of immunotherapy and at the end of study
blood samples for analysis of safety laboratory values were
collected and an ECG was performed. At all visits, a phys-
ical examination of the nose and mouth was performed
and vital signs were checked.
Statistical analysis
All analysis were performed both on the intention-to-
treat (ITT) and per protocol (PP) population.
For the primary analysis the proportions of subjects,
showing a beneficial treatment effect , were compared
between the two treatment groups. A non-inferiority ap-
proach was chosen, using a non-inferiority margin of
30%. For investigation of a difference in treatment suc-
cess the following hypotheses were tested:
H0: πStal - πSubl ≥ 0.3 vs. H1: πStal - πSubl < 0.3,
whereby πSubl and πStal denote the proportions of subjects,
showing a beneficial treatment effect after SUB-B and Stal-
B treatment, respectively. The one-sided 97.5% confidence
interval for the difference in proportions between the two
treatment groups was determined. H0 would be rejected if
Figure 1 Disposition of patients.
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bal α-level for this study was 0.025 one sided.
For the results of specific immunoglobulin levels, com-
parison of the treatment groups was performed using
the Wilcoxon rank sum test (two-sided). Analogous to
this, pre-post differences for specific immunoglobulin
levels before and after treatment were calculated.
For safety measurement the rate of subjects with at least
one AE was compared between groups using Fisher’s exact
test. Regarding safety laboratory values and vital signs a
baseline comparison between treatment groups was per-
formed using Wilcoxon rank sum test. Furthermore, shift
analyses to show changes before and after treatment for
safety laboratory values, ECG, vital signs and physical ex-
aminations were performed. For the secondary outcome
measures an α -level <0.05 was considered significant.With a sample size of 28 subjects per group, using a one-
sided 0,025 significance level and non-inferiority margin of
30%, a power 80% was reached to reject the null hypothesis
that the SUB-B and Stal-B are not equivalent.
Results
Study population
A total of 122 subjects were screened and 74 subjects
(safety population) were randomized and assigned to
treatment with either SUB-B (n = 38) or Stal-B (n = 36).
Three out of 74 subjects were assigned as not eligible and
excluded from the analysis, since no post-baseline data
were available (ITT population). In the ITT population the
SUB-B treatment group consisted of 36 and the Stal-B
treatment group of 35 subjects. Eight subjects terminated
the study prematurely: 2 subjects were lost to follow-up, 1
Table 3 Treatment effect assessed by change in TNPT
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least ‘possible’ relationship to the study medication and 5
subjects withdrew informed consent (SUB-B n = 6; Stal-B
n = 2; Figure 1).
Demographic data and baseline characteristics for both
the ITT and PP population are provided in Table 2.
SUB-B 33.3% (12) 47.2% (17) 19.4% (7) 45.8% (11) 54.2% (13)
Stal-B 31.4% (11) 54.3% (19) 14.3% (5) 35.0% (7) 65.0% (13)
aIncorrect assessment of baseline TNPT leading to violation of inclusion criteria.Efficacy
The change in the threshold dose of the titrated nasal
provocation test before and after treatment with either
SUB-B or Stal-B was determined per subject for both
the ITT and the PP population. If the second TNPT was
scored positive at a higher dose or even stayed negative
at the highest dose tested, this indicated that subjects
were less sensitive to birch pollen (=beneficial). The per-
centage of subjects showing a beneficial treatment effect
was 33.3% (12/36 subjects) vs. 31.4% (11/35 subjects) in
the ITT population and 45.8% (11/24 subjects) vs. 35.0%
(7/20 subjects) in the PP population following SUB-B
and Stal-B treatment, respectively. The results for both
the ITT and PP population are displayed in Table 3. The
one-sided 97.5% confidence interval for the difference in
proportions between the two treatment groups (−1─0.181)
lies completely below 0.3 indicating non-inferiority.
Analogously, analysis of the symptom scores after
nasal allergen showed a decrease of the mean symptom
scores following both SLIT treatments in the ITT popu-
lation (Figures 2 and 3). Not every patient received the
same doses pre- and post-treatment (depended on the
response). In addition, the 10,000 AU/ml dose was only
administered at the end of the study. Therefore, no stat-
istical analysis was performed on the mean decrease in
overall symptom scores. However, if we compare the
mean decrease in symptom scores over concentration
10–1,000 AU/ml a 45% vs. 43% decrease in symptom
score was observed in the SUB-B and Stal-B treatment
group compared to baseline, respectively.Table 2 Demographic and baseline characteristics of the
study population
ITT population Safety population
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75.0% 80.0% 76.3% 77.8%
Mean ± SD. ªSensitization to allergens other than tree pollen.In both treatment groups a similar decrease in flow re-
duction after each allergen challenge dose was observed
following treatment.Specific immunological response
IgE, IgG and IgG4 specific for birch (Bet v) and Bet v 1
were determined per subject at the baseline visit (pre-
treatment) and at the end of study visit (post-treatment)
for both treatment groups.
A comparable increase in birch (Bet v) and Bet v 1 spe-
cific IgE was observed in both treatment groups (Figure 4).
Particularly specific IgG (Figure 5) and IgG4 (Figure 6)
levels increased significantly (between 1.8 and 2.8 times)
after treatment in both groups. Apart from Bet v specific
IgG levels, no significant differences were detected in the
increase of immunoglobulin levels between SUB-B and
Stal-B treatment. Similar results were obtained in the PP
population (data not shown).Safety
Treatment was well tolerated in both treatment groups,
no unexpected AEs were observed. In total, 75.7% of all
subjects (56/74) experienced a treatment-emergent AE,
28/38 (73.7%) treated with SUB-B and 28/36 (77.8%)
treated with Stal-B. There was no significant differenceFigure 2 Mean symptom scores following TNPT before and after
treatment with SUB-B B (ITT population, n = 36). The 10,000 AU/ml
challenge was only given during the 2nd TNPT if the challenge at
1,000 AU/ml was negative.
Figure 3 Mean symptom scores following TNPT before and after
treatment with Stal-B (ITT population, n = 35). The 10,000 AU/ml
challenge was only given during the 2nd TNPT if the challenge at
1,000 AU/ml was negative.
Figure 5 Bet v specific IgG levels (including standard error)
before and after SLIT treatment. Bet v specific IgG levels increased
in both groups, the increase in the SUB-B groups was significantly higher
than in the Stal-B group (p = 0.03).
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ment groups (p = 0.80).
Of the 164 AEs, 143 were related to the study medica-
tion (SUB-B n = 79, Stal-B n = 64). The majority of the
related AEs was of grade I (mild) intensity in both treat-
ment groups. The most common reported AEs were
pruritus/swelling of mouth, tongue or lip (SUB-B: 65.8%
of subjects; Stal-B: 61.1% of subjects). The pattern of
AEs observed for both SLIT treatments was similar
(Table 4). Symptom/sign designation was performed ac-
cording to WAO grading of local and systemic adverse
events [16-18].
During the study, one SAE was reported, which was
assessed as not related to the study medication. Further-
more, no clinically relevant changes in safety laboratory
parameters, vital signs, physical examination of the
mouth and nose, and ECGs were observed and no statis-
tical significant differences in these parameters between
treatment groups were detected.Figure 4 Bet v and Bet v 1 specific IgE levels (including
standard error) before and after SLIT treatment. No significant
differences in the increase in Bet v (p = 0.62) and Bet v 1 (p = 0.63)
specific IgE levels was observed following SUB-B and Stal-B treatment.Discussion
It has been acknowledged that the clinically effective
doses of allergens for SLIT must be higher than for
SCIT [1]. The amount of allergen administered is crucial
for both efficacy and safety of specific immunotherapy
and dose dependency has been reported [12]. The
present study was designed to investigate the clinical ef-
ficacy and safety of SUB-B, containing a high dose of the
birch pollen major allergen Bet v 1. Analysis of the re-
sults showed that the percentage of subjects showing a
beneficial treatment effect was 45.8% vs. 35.0% in the PP
population and 33.3% vs. 31.4% in the ITT population
following SUB-B and Stal-B treatment, respectively.
Since no significant differences between both treatment
groups were observed, non-inferiority of SUB-B com-
pared to Stal-B was concluded. Evaluation of the im-
munologic response, showed that treatment with both
products induced a similar increase in IgG and IgG4Figure 6 Bet v and Bet v1 specific IgG4 levels (including standard
error) before and after SLIT treatment. No significant differences in
the increase in Bet v (p = 0.17) and Bet v 1 (p = 0.11) specific IgG4 levels
was observed following SUB-B and Stal-B treatment.














Pruritus/swelling of mouth, tongue or lip I 44 24 63.2 31 22 61.1
II 1 1 2.6 0 0 0
Throat irritation I 4 3 7.9 5 2 5.6
Ear pruritus I 4 4 10.5 3 1 2.8
Nausea I 3 2 5.3 0 0 0
Abdominal pain I 3 3 7.9 1 1 2.8
Systemic reactions
Upper respiratory
Rhinitis (e.g., sneezing, rhinorrhea, nasal pruritus, and/
or nasal congestion)
I 10 5 13.2 8 6 16.7
Cough I 2 2 5.3 1 1 2.8
Conjunctival
Conjunctival erythema, pruritus , or tearing I 2 2 5.3 3 2 5.6
Other
Headache I 1 1 2.6 3 2 5.6
aSymptom/sign designation according to WAO grading of local and systemic adverse events [16-18].
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Moreover, non-inferiority was also shown for the
treatment effect on the immunological response. In
addition, safety analysis shows that both products
are safe and cause mainly mild (grade I) and transi-
ent AEs.
The high and unpredictable variation in pollen levels
and exposure to pollen may hamper the assessment of the
efficacy, therefore it was decided to perform an explora-
tory comparison with a registered product (Stal-B), based
on a surrogate parameter (TNPT). We chose the TNPT,
since the response to nasal challenges has been shown to
correlate to symptom-medication scores during the season
and provocation tests are accepted endpoints in dose
range finding studies [8,19]. In addition, nasal provocation
tests can be combined with objective evaluation parame-
ters such as rhinomanometry or peak nasal inspiratory
flow (PNIF) [20]. In this single-centre study rhinomano-
metry was chosen, in multi-centre studies PNIF is a more
suitable parameter. The reduction in TNPT response
found in this study is therefore likely to be clinically rele-
vant and translate into a decrease in seasonal symptoms
for both allergen-preparations though this trial was not
designed to investigate seasonal clinical efficacy by analyz-
ing combined symptom-medication scores [8].
Although no differences between both treatment
groups were observed, the percentage of subjects showing a
beneficial treatment effect in the TNPT, i.e. an increase in
the provocative threshold dose, was expected to be slightly
higher in both treatment groups. This might be explainedby the short treatment duration (on average 16 weeks on
maintenance dose).
From the specific IgG assessments, a two-fold increase
in specific IgG/IgG4 concentrations was observed in
both treatment groups, supporting the immunogenic ef-
fect of both products. These results are comparable with
the increase in IgG levels reported after sublingual im-
munotherapy with Staloral Birch [21]. Similarly, in a
study with grass pollen SLIT the increase was also ap-
proximately two-fold after four months. However, the ef-
fect on the immunologic parameters was shown to be
progressive with almost a fourfold increase after three
treatment years [22]. Although the link between im-
munologic changes and clinical efficacy is not clarified
as yet, this might suggest that the treatment duration
in the present study was too short and longer treat-
ment will result in maximal clinical and immunological
effects.
Regarding safety, both the number of subjects experi-
encing AEs, and the frequency and nature of AEs were
similar for both treatment with SUB-B and Stal-B. The
majority of adverse reactions were of grade I (mild) in-
tensity and all the patients fully recovered. Furthermore,
no clinically relevant changes in safety laboratory param-
eters, vital signs, physical examination of the mouth and
nose, and ECGs were observed. These results are com-
parable with results in other studies where SLIT has
consistently shown to be safe and most adverse reactions
are mild and occur during the induction phase of treat-
ment both in paediatric patients and adults [6,23]. The
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mucosa and of the gastrointestinal system. Furthermore,
during the study no clinically relevant changes in safety
laboratory parameters, vital signs, physical examination
of the mouth and nose, and ECGs were observed.
In conclusion, treatment with SUB-B was demonstrated
to be as effective as treatment with Stal-B by means of re-
duction in allergic symptoms during nasal provocation in
subjects suffering from IgE mediated allergic complaints
triggered by birch pollen. In addition, SLIT with both prep-
arations revealed a good safety-profile.
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